ASP Isotopes Inc. (NASDAQ: ASPI) is a pre-commercial stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”). The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes). There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. Watch ASPI’s Parker Scott at Emerging Growth Here
Catheter Precision, Inc. (NYSE American: VTAK), a cutting-edge medical technology firm, revealed on December 5 that it had received an invitation to present at the Emerging Growth Conference scheduled for December 6, 2023. During the event, Catheter Precision will spotlight its groundbreaking non-invasive 3D mapping system, VIVO™, designed to assist physicians in pinpointing the source of ventricular arrhythmias before medical procedures while enhancing workflow efficiency and shortening procedure durations. This cost-effective and innovative remedy has obtained regulatory approval from the United States Food and Drug Administration (FDA) and is currently accessible for commercial use in Europe.
Watch VTAK’s David Jenkins at Emerging Growth Here
Furthermore, VIVO™ 3D Mapping System’s revolutionary potential was recently featured by “Cardiac Rhythm News” see complete news article: https://cardiacrhythmnews.com/catheter-precisions-vivo-3d-mapping-system-secures-reimbursement-in-nhs-englands-ssdp/
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a life sciences company. The Company is engaged in developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It operates through two segments, namely Commercially available Intelligent Fingerprinting Products (IFPG) and Development Stage Saliva Glucose Biosensor Platform (SGBP). Its product portfolio includes a portable drug screening system that works by analyzing fingerprint sweat using a one-time cartridge and portable handheld reader and also includes a development stage range of biosensor- based Point of Care diagnostic tests (POCT) that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology. Its product candidate is the Saliva Glucose Biosensor (SGB), a POCT expected to substitute the finger pricking invasive blood glucose monitoring for diabetic patients. Its Biosensor Platform helps to detect multiple biological analytes. Watch INBS’Harry Simeonidis, President / CEO at Emerging Growth Here
Houston Natural Resources Corp (OTC: HNRC) stands as a versatile energy enterprise with stakes in both oil and gas. Notably, the company has successfully obtained full ownership, a 100% interest, in Cunningham Energy LLC, boasting appraised reserves totaling $352 million. Additionally, Houston Natural Resources Corp holds minority investments in Rhino Energy Ltd, CE Energy Sponsors, LLC, and HNR Acquisition Corp. The company encompasses mining ventures in copper, lithium, gold, as well as other valuable and rare earth metals. With a global perspective, the investment strategy is underpinned by a commitment to sustainability, making it an integral element of the company’s core approach. Demonstrating a commitment to growth, the company remains proactive in its pursuit of new opportunities within the energy and energy transitions sectors, all with the overarching goal of delivering enhanced value to its shareholders. Watch HNRC’s Frank Kristan, Chairman & CEO at Emerging Growth Here
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.